You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康暫停新冠疫苗試驗,因英國一研究對象出現疾病

《華爾街日報》報道,阿斯利康週二稱,由於英國一項研究中的一名對象出現不明原因疾病,該公司暫停了一種試驗性新冠疫苗的臨牀試驗。

阿斯利康表示,此次暫停將允許一個獨立委員會對安全性數據進行審查。該疫苗來自牛津大學,阿斯利康獲得了研發人員對該疫苗的許可。

這一暫停影響了上週在美國開始的一項研究,該研究由美國聯邦機構資助,旨在招募3萬名研究對象。該研究正在測試,與未接種疫苗的研究對象相比,該疫苗是否能減少新冠病毒感染人數。

阿斯利康與牛津大學聯合開發的這種新冠疫苗被視爲有望投放市場的主要候選疫苗之一。受暫停消息影響,導致阿斯利康在紐約盤後交易大跌8.15%,同時提振了其他新冠疫苗開發競爭對手的股價,美股Moderna盤後漲4.34%、港股康希諾生物-B今日一度漲超5%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account